Trial Profile
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Acitretin; Adalimumab; Antipsoriatics; Ciclosporin; Etanercept; Methotrexate; Psoralens
- Indications Plaque psoriasis; Psoriasis; Psoriatic arthritis
- Focus Adverse reactions
- Acronyms PSOLAR
- Sponsors Janssen Biotech
- 28 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Sep 2022 Planned End Date changed from 31 Dec 2031 to 31 Dec 2030.
- 23 Nov 2021 Planned End Date changed from 31 Dec 2030 to 31 Dec 2031.